Last updated date
ABOUT THIS STUDY
To investigate the following matters under post-marketing use of Lorbrena in patients who
received this drug
1. Factors affecting the onset of central nervous system disorder
2. Effect of Lorbrena in combination with CYP3A inducers on the onset of hepatic
dysfunction
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Non-small Cell Lung Cancer
Sex
Females and Males
Age
0 +
Inclusion Criteria
Show details
- All administered patients
Exclusion Criteria
Show details
- Nothing
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Non-Small Cell Lung CancerStudy of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
NCT02920450
- Gainesville, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerEffect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
NCT00300729
- Gothenburg,
- Jönköping,
- Kalmar,
- Linköping,
- Lund,
- Malmö,
- Skövde,
- Trollhättan,
- Uddevalla,
- Umeå,
- Uppsala,
- Ystad,
- Örebro,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerA Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00555256
- St. Louis, Missouri
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-small Cell Lung CancerAn Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
NCT03915951
- Altamonte Springs, Florida
- Bonita Springs, Florida
- Bradenton, Florida
- Brandon, Florida
- Cape Coral, Florida
- Clearwater, Florida
- Fleming Island, Florida
- Fort Myers, Florida
- Fort Myers, Florida
- Gainesville, Florida
- Largo, Florida
- Lecanto, Florida
- Naples, Florida
- New Port Richey, Florida
- Ocala, Florida
- Orange City, Florida
- Orlando, Florida
- Port Charlotte, Florida
- Saint Petersburg, Florida
- Sarasota, Florida
- Sarasota, Florida
- Spring Hill, Florida
- Tallahassee, Florida
- Tampa, Florida
- Tavares, Florida
- The Villages, Florida
- Venice, Florida
- Winter Park, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Johns Creek, Georgia
- Overland Park, Kansas
- Baltimore, Maryland
- Baltimore, Maryland
- Creve Coeur, Missouri
- Independence, Missouri
- Kansas City, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- New York, New York
- New York, New York
- Durham, North Carolina
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Gahanna, Ohio
- Lewis Center, Ohio
- Clackamas, Oregon
- Newberg, Oregon
- Chattanooga, Tennessee
- Cleveland, Tennessee
- Dickson, Tennessee
- Franklin, Tennessee
- Gallatin, Tennessee
- Hendersonville, Tennessee
- Hermitage, Tennessee
- Lebanon, Tennessee
- Murfreesboro, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Shelbyville, Tennessee
- Smyrna, Tennessee
- Kingwood, Texas
- The Woodlands, Texas
- Roma, Lazio
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Orbassano, Torino
- Napoli,
- Torino,
- Barcelona,
- Cordoba,
- Cordoba,
- Esplugues de Llobregat,
- L'Hospitalet,
- Malaga,
- Sevilla,
- Los Angeles, California
- Santa Monica, California
- Norwich, Connecticut
- Norwich, Connecticut
- Norwich, Connecticut
- Putnam, Connecticut
- Fort Myers, Florida
- Saint Petersburg, Florida
- Tallahassee, Florida
- Venice, Florida
- Atlanta, Georgia
- Chicago, Illinois
- Overland Park, Kansas
- Baltimore, Maryland
- Baltimore, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Chelsea, Massachusetts
- Danvers, Massachusetts
- Marlborough, Massachusetts
- Stoneham, Massachusetts
- Stoneham, Massachusetts
- Waltham, Massachusetts
- Independence, Missouri
- Kansas City, Missouri
- Saint Louis, Missouri
- Basking Ridge, New Jersey
- Hackensack, New Jersey
- Montvale, New Jersey
- Bronx, New York
- Bronx, New York
- Bronx, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- Portland, Oregon
- Portland, Oregon
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- York, Pennsylvania
- York, Pennsylvania
- Chattanooga, Tennessee
- Chattanooga, Tennessee
- Houston, Texas
- Houston, Texas
- Shenandoah, Texas
- Seattle, Washington
- Faenza, Emilia-romagna
- Lugo, Emilia-romagna
- Ravenna, Emilia-romagna
- Ravenna, Emilia-romagna
- Rimini, Emilia-romagna
- Milano, Lombardia
- Milano, Lombardia
- Napoli, Naples
- Cattolica, Rimini
- Orbassano, Torino
- Bologna,
- Milano,
- Naples,
- Goyang-si, Gyeonggido
- Jeonnam,
- Seoul,
- Seoul,
- Seoul,
- Amsterdam, Noord-holland
- Amsterdam, Noord-holland
- Groningen,
- Hospitalet de Llobregat, Barcelona
- L'Hospitalet de Llobregat, Barcelona
- L'Hospitalet de Llobregat, Barcelona
- Majadahonda, Madrid
- Malaga, Málaga
- Barcelona,
- Barcelona,
- Barcelona,
- Barcelona,
- Hospitalet de Llobregat,
- Madrid,
- Madrid,
- Sevilla,
- Sevilla,
- Sevilla,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | |||||
---|---|---|---|---|---|
Brief Title | Safety and Efficacy of Lorbrena | ||||
Official Title | Special Investigation for LORBRENA Tablets | ||||
Brief Summary | To investigate the following matters under post-marketing use of Lorbrena in patients who received this drug
| ||||
Detailed Description | Not Provided | ||||
Study Type | Observational | ||||
Study Design | Observational Model: Case-Only Time Perspective: Prospective | ||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Not Provided | ||||
Sampling Method | Probability Sample | ||||
Study Population | 651 patients | ||||
Condition | Non-small Cell Lung Cancer | ||||
Intervention | Not Provided | ||||
Study Groups/Cohorts | Not Provided | ||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
Recruitment Information | |||||
Recruitment Status | Recruiting | ||||
Estimated Enrollment | 651 | ||||
Original Estimated Enrollment | Same as current | ||||
Estimated Study Completion Date | August 11, 2023 | ||||
Estimated Primary Completion Date | August 11, 2023 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| ||||
Sex/Gender |
| ||||
Ages | Child, Adult, Older Adult | ||||
Accepts Healthy Volunteers | No | ||||
Contacts |
| ||||
Listed Location Countries | Japan | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT03844464 | ||||
Other Study ID Numbers | B7461018 | ||||
Has Data Monitoring Committee | Not Provided | ||||
U.S. FDA-regulated Product | Not Provided | ||||
IPD Sharing Statement |
| ||||
Responsible Party | Pfizer | ||||
Study Sponsor | Pfizer | ||||
Collaborators | Not Provided | ||||
Investigators |
| ||||
PRS Account | Pfizer | ||||
Verification Date | June 2020 |